BioWorld

March 29, 2010

View Archived Issues

Cardio-Renal Player CorMedix Raises $12.5M in AMEX Debut

CorMedix Inc. caught much of the biotech industry by surprise late Thursday when the relatively obscure cardio-renal specialty pharma firm priced a $12.5 million initial public offering on AMEX. (BioWorld Today) Read More

Biovail Expands CNS Pipeline, Paying $10M for Cortex Drugs

Read More

Much-Needed Financing Adds $49.5M for Somaxon's Silenor

Read More

GAO: FDA Management Faults Carries Risks for Consumers

Read More

Clinic Roundup

Read More

Vital Signs

Read More

Other News To Note

Read More

Stock Movers

Read More

Appointments And Advancements

Read More

Bench Press

Read More